Arbutus Biopharma Corporation (NASDAQ:ABUS) traded at $2.92 at last check on Tuesday, Sep 15, making an upward move of 11.41% on its previous day’s price.
Looking at the stock we see that its previous close was $2.62 and the beta (5Y monthly) reads 2.9 with the day’s price range being $2.8300 – 3.3899. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, ABUS has a high of $9.02 and a low of $0.82. The company’s stock has gained about -23.62% over that past 30 days.
On the other hand, looking at the outlook for the ABUS stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 5 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Arbutus Biopharma Corporation (ABUS) stock as a Hold, while 4 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the ABUS stock currently stands at 0, and the current price level is 1.53% off its SMA20 and -5.61% from its 50-day simple moving average. The RSI (14) is pointing at 52.81 while the volatility over the past week is 9.38% and drops to 7.09% over the past one month. The beta value is 2.9, while the average true range (ATR) is currently pointing at 0.27. The average price target for the stock over the next 12 months is $6, with the estimates having a low of $4 and a high of $8. These price ends are 36.99% and +173.97% off the current price level respectively, although investors could be excited at the prospect of a +71.23% if the ABUS share price touches on the median price of $5.
Let’s briefly compare Arbutus (ABUS) stock to its peers. We find that today’s price change of +11.41% and +56.89% over the past 12 months for ABUS betters that of Amgen Inc (AMGN), which has seen its stock price rise 1.43% in the latest trading session and is +26.23% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has dropped -0.29% today, and is +20.78% up over the past year, while Gilead Sciences Inc (GILD) is also up 11.41% yet its price remains in the green at 56.89% over the same period. Amgen has a P/E ratio of 20.16 compared to Arbutus 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.93% and 0.43%, respectively, in early deals.
Coming back to Arbutus Biopharma Corporation (NASDAQ:ABUS), we note that the average 3-month trading volume was 8.82 Million, while that of the preceding 10-day period stands at 1.29 Million. Current shares outstanding are 80.91 Million.
According to data from Thomson Reuters, insiders hold 30.16% of the company’s shares while institutions hold 35.04%. The data shows that short shares as of August 30, 2020, stood at 2.62 Million at a short ratio of 0.57. This represents a 3.12% Short interest in Shares outstanding on August 30, 2020. Shares short rose in August from the previous month at 1.97 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -5.76% down in year-to-date price movement.